Oncotelic Therapeutics, Inc. 8-K

What Happened
On March 24, 2026, Oncotelic Therapeutics, Inc. announced that Sapu Nano — a company in which Oncotelic holds a minority interest — will introduce its Deciparticle™ nanomedicine platform and highlight its advancing clinical pipeline at Bio‑Europe Spring 2026 on March 25, 2026. Oncotelic furnished a press release about this development in a Form 8-K filed March 30, 2026.

Key Details

• Announcement date: March 24, 2026; presentation date: March 25, 2026 (Bio‑Europe Spring 2026).
• Oncotelic holds a minority interest in Sapu Nano (no percentage disclosed in the 8-K).
• Press release describing the Deciparticle platform and pipeline was attached as Exhibit 99.1 to the Form 8-K.
• The information was furnished to the SEC and is expressly stated not to be “filed” under Section 18 of the Exchange Act.

Why It Matters
This disclosure keeps investors informed about a portfolio company (Sapu Nano) activity that could affect Oncotelic’s minority investment visibility and potential future value. The presentation of Sapu Nano’s Deciparticle platform at a major industry event may increase awareness of the technology and its clinical progress, but the 8-K does not provide financial details, timelines, outcomes, or changes to Oncotelic’s financial statements. Investors should view this as a corporate update about an affiliated company rather than a direct operational or financial change for Oncotelic.